Anteris Technologies (ASX:AVR) said its biomimetic DurAVR transcatheter heart valve (THV) has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.
Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.
The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.
Shares were down 6% in morning trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.